These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39416967)

  • 21. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
    Yang W; Feng Y; Zhou J; Cheung OK; Cao J; Wang J; Tang W; Tu Y; Xu L; Wu F; Tan Z; Sun H; Tian Y; Wong J; Lai PB; Chan SL; Chan AW; Tan PB; Chen Z; Sung JJ; Yip KY; To KF; Cheng AS
    Sci Transl Med; 2021 Apr; 13(588):. PubMed ID: 33827976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
    Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
    PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
    Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
    Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
    Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
    J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
    Shin HS; Choi J; Lee J; Lee SY
    Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Moris D; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Dec; 27(4):611-618. PubMed ID: 30449480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
    Garmpis N; Damaskos C; Garmpi A; Georgakopoulou VE; Sarantis P; Antoniou EA; Karamouzis MV; Nonni A; Schizas D; Diamantis E; Koustas E; Farmaki P; Syllaios A; Patsouras A; Kontzoglou K; Trakas N; Dimitroulis D
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
    Sanaei M; Kavoosi F
    Asian Pac J Cancer Prev; 2021 Feb; 22(S1):89-95. PubMed ID: 33576217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
    Tang C; Du Y; Liang Q; Cheng Z; Tian J
    Mol Imaging Biol; 2020 Jun; 22(3):476-485. PubMed ID: 31228075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
    Dong S; Ma X; Wang Z; Han B; Zou H; Wu Z; Zang Y; Zhuang L
    Oncotarget; 2017 Jun; 8(25):40583-40593. PubMed ID: 28489564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
    Buurman R; Sandbothe M; Schlegelberger B; Skawran B
    Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
    Llopiz D; Ruiz M; Villanueva L; Iglesias T; Silva L; Egea J; Lasarte JJ; Pivette P; Trochon-Joseph V; Vasseur B; Dixon G; Sangro B; Sarobe P
    Cancer Immunol Immunother; 2019 Mar; 68(3):379-393. PubMed ID: 30547218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.